Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Mylan's Fulphila Sets Up The US Market For The Next Biosimilar Showdown

Jul 12 2018

• By Jessica Merrill

CANONSBURG, PENNSYLVANIA, USA - AUGUST 17: Exterior of Mylan Global Headquarters on August 17, 2017 in Canonsburg, PA. Mylan is in the news over pricing of the Epipen.

Related Content

Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts

Sep 20 2017

Mylan Is First To Clear US Neulasta Biosimilar Hurdle; At-Risk Launch May Not Be Risky

Jun 05 2018

FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market

Mar 08 2018

Exclusive Remicade Contracts Are Slowing Biosimilar Uptake

Aug 01 2017

Mylan Poised To Launch Its First US Biosimilar, With A Stacked Pipeline Behind It

Apr 12 2018

Related Companies

Viatris Inc.

Amgen, Inc.

Pfizer Inc.

Johnson & Johnson

Teva Pharmaceutical Industries Ltd.

Additional Topics

Biosimilars Launches Pricing Strategies Commercial BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window